Table 1 Demographics and baseline characteristics
Characteristic | Patients, n (%) |
|---|---|
Age, years, median (range) | 59(28–73) |
Sex | |
Male Female | 23(76.7) 7(23.3) |
ECOG PS* | |
0 1 2 | 4(13.3) 25(83.3) 1(3.3) |
Primary tumor sites | |
Lower esophagus Cardiac and gastric fundus Gastric body Gastric antrum | 1(3.3) 7(23.3) 13(43.3) 9(30.0) |
Cancer grading | |
G1 G2 G3 | 0(0) 5(16.7) 25(83.3) |
Lauren typing | |
Intestinal type Diffuse type Mixed type or unknown | 9(30.0) 14(46.7) 7(23.3) |
Metastatic sites | |
Lymph node Peritoneum Liver Bone Lung | 19(63.3) 9(30.0) 8(26.7) 2(6.7) 1(3.3) |
Prior treatment regimens | |
First-line Second-line Platinum and Fluorouracil Taxanes | 25(83.3) 5(16.7) 29(96.7) 7(23.3) |
MMR/MSI* | |
MMR deficient MMR proficient | 0(0) 30(100.0) |
HER2* | |
0 1+ 2+/FISH*(-) | 22(73.3) 4(13.3) 4(13.3) |
EBER* | |
Negative Positive | 30(100.0) 0(0) |